Nordic Capital acquires majority share in IntegriChain, the only fully integrated platform for pharma commercialization and market access

Nordic Capital
  • Investment will accelerate IntegriChain’s ambitious growth targets and cement its status as a leading platform for pharma manufacturers to bring their science to market 
  • Further strengthens Nordic Capital’s record as a leading healthcare and technology investorNordic Capital has signed an agreement to acquire a majority share in IntegriChain, a leading provider of pharmaceutical technology, data, consulting, and outsourcing solutions designed to improve how life sciences products reach customers. IntegriChain delivers pharma’s only fully integrated platform for commercialization and market access, helping manufacturers bring their science to market while ensuring patients have affordable, timely, and sustainable access to therapy. Nordic Capital is acquiring the majority stake from Accel-KKR, a global software private equity firm, which first invested in IntegriChain in 2016.IntegriChain’s integrated ICyte Platform helps connect the commercial, financial, and operational dimensions of drug access and profitability. ICyte enables pharmaceutical innovators to achieve better commercial outcomes by digitalizing daily and recurring business activities and integrating data and operations across contracting, pricing, channel and distribution, and gross-to-net.

    “IntegriChain has established a significant position over the last 17 years as a leader in access and commercialization for life sciences – helping manufacturers of all size from strategy to operational execution. We are confident that the company will continue its already strong record of growth by helping customers address their most pressing market access challenges as the industry evolves. The fact that IntegriChain supports more than 400 pharmaceutical customers speaks to the quality of the platform, data, and services they provide. We’re certain that Nordic Capital’s experience supporting companies with similar ambitions, our extensive industry networks, and deep-sector knowledge will take the company to even greater heights,” said Daniel Berglund, Co-Head of Healthcare, Nordic Capital Investment Advisors.

    Josh Halpern, Co-Founder and CEO of IntegriChain, said: “We’re pleased to have Nordic Capital as a new partner to support us on our journey. We are immensely proud of the team at IntegriChain and how we help pharma manufacturers deliver winning commercialization strategies while optimizing their net revenue. With Nordic Capital’s invaluable healthcare and technology experience and expertise, I’m confident that this partnership will enable us to extend our position as a leading platform for pharma manufacturers to bring their science to market. We thank Accel-KKR for their many years of sound guidance and support to help us ready IntegriChain for this important next phase of our business development.”

    The terms of the transaction were not disclosed. Completion of the transaction is expected before year end and is subject to customary closing conditions, including relevant regulatory approvals.

    Morgan Stanley & Co. LLC and Harris Williams LLC are acting as financial advisors to IntegriChain. Evercore is acting as financial advisor to Nordic Capital.


    Media contacts:

    Nordic Capital
    Katarina Janerud
    Communications Manager, Nordic Capital Advisors
    Tel: +46 8 440 50 50
    e-mail: katarina.janerud@nordiccapital.com

    IntegriChain
    Jennifer Guinan
    Sage Strategic Marketing
    +1 610.425.8659
    jennifer@sagestrat.com


    About IntegriChain
    IntegriChain helps pharma manufacturers bring their science to market, ensuring patients have affordable, timely, and sustainable access to therapy. IntegriChain delivers Pharma’s only data-driven commercialization platform — from strategy to operational execution. The Company’s unique focus on data, technology, consulting, and outsourcing helps connect the commercial, financial, and operational dimensions of drug access and profitability. Through the ICyte Platform, IntegriChain enables pharmaceutical innovators to achieve better commercial outcomes by digitalizing daily and recurring business activities and by integrating data and operations across contracting, pricing, channel and distribution, and gross-to-net. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm, and is headquartered in Philadelphia, PA, with offices in Ambler, PA, and Pune, India. For more information, visit www.integrichain.com or follow on LinkedIn.


    About Nordic Capital

    Nordic Capital is a leading private equity investor with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a long history. Focus sectors are Healthcare, Technology & Payments, Financial Services, and selectively, Industrial & Business Services. Key regions are Europe and globally for Healthcare and Technology & Payments investments. Since inception in 1989, Nordic Capital has invested EUR 23 billion in 140 investments. The most recent entities are Nordic Capital XI with EUR 9.0 billion in committed capital and Nordic Capital Evolution with EUR 1.2 billion in committed capital, principally provided by international institutional investors such as pension funds. Nordic Capital Advisors have local offices in Sweden, the UK, the US, Germany, Denmark, Finland, Norway, and South Korea. For further information about Nordic Capital, please visit www.nordiccapital.com.

    “Nordic Capital” refers to, depending on the context, any, or all, Nordic Capital branded entities, vehicles, structures, and associated entities. The general partners and/or delegated portfolio managers of Nordic Capital’s entities and vehicles are advised by several non-discretionary sub-advisory entities, any or all of which are referred to as “Nordic Capital Advisors”

     

    About Accel-KKR

    Accel-KKR is a technology-focused investment firm with $19 billion in cumulative capital commitments. The firm focuses on software and tech-enabled businesses, well-positioned for top-line and bottom-line growth. At the core of Accel-KKR’s investment strategy is a commitment to developing strong partnerships with the management teams of its portfolio companies and a focus on building value alongside management by leveraging the significant resources available through the Accel-KKR network. Accel-KKR focuses on middle-market companies and provides a broad range of capital solutions, including buyout capital, minority-growth investments, and credit alternatives. Accel-KKR also invests across various transaction types, including private company recapitalizations, divisional carve-outs, and going-private transactions. Accel-KKR’s headquarters is in Menlo Park, with offices in Atlanta, London, and Mexico City. Visit accel-kkr.com to learn more.

Categories: News

Tags:

KKR and Flerie form specialized pharma services platform Frontier Biosolutions and invest in Coriolis Pharma

KKR
  • KKR and Flerie to support organic and inorganic growth to extend Coriolis’ leadership position in formulation development and analytical services for innovative high-value biologics and cell and gene therapy products
  • Experienced team of biopharma services veterans led by Thomas Eldered of Flerie Invest AB (“Flerie”) to provide strategic advice and operational support to Frontier’s portfolio companies, including Coriolis

MUNICH–(BUSINESS WIRE)– KKR, a leading global investment firm, today announced, in partnership with Flerie, the formation of a new global pharma services platform, Frontier Biosolutions (“Frontier”), which will invest in a portfolio of companies focused on specialized pharmaceutical services to advanced therapeutics customers. Frontier will invest in differentiated scientific capabilities and proprietary technology platforms that address critical bottlenecks in the development and manufacturing of advanced therapeutics.

Industry veteran and co-investor Thomas Eldered will serve as Frontier’s Executive Chairman, bringing more than 34 years of senior management expertise to the management board and drawing on his experience as Co-founder of Recipharm and as a life sciences investor at Flerie. He will be joined by Mark Quick, formerly Head of M&A at Recipharm now Partner at Flerie, Stephan Kutzer, formerly CEO at Alcami and Divisional CEO and COO at Lonza Pharma and Biotech, Danielle Young, formerly Head of Commercial Strategy at Alcami, and Phil Vanek, currently CTO at Gamma Biosciences.

As the platform’s foundational investment, funds managed by KKR and Flerie, through Frontier, have invested in Munich-based Coriolis Pharma, a global leader in formulation research and development, analytical services and non-GMP manufacturing of innovative high-value biologics and cell and gene therapy products. With its scientific expertise, Coriolis enables its clients to create high quality drug products with global commercial potential from early development to product commercialization. KKR’s investment will enable Coriolis’ continued expansion, especially into the fast-growing cell and gene therapy segment and will expand its range of services offered to customers globally.

“We are thrilled to partner with Flerie and Thomas Eldered, the experienced Board of Directors, and the team at Coriolis Pharma at a time of growing demand for specialized services to support the development of advanced therapeutics,” said Kugan Sathiyanandarajah, Managing Director and Head of KKR’s Health Care Strategic Growth business in Europe. “This platform and the investment in Coriolis Pharma are another example of our Health Care Strategic Growth platform strategy to partner with proven operators in an area we have been following for some time.”

“We are very excited to launch Frontier Biosolutions as a global platform that we believe will enable its future portfolio companies to understand and address the evolving needs in drug development,” said Thomas Eldered. “Coriolis Pharma has an industry-leading track record as a global provider of mission-critical, highly specialized formulation development services and a reputation for scientific leadership and complex problem solving. I look forward to working with the outstanding management team at Coriolis as they pursue their ambitious growth plans.”

Michael Wiggenhorn, Co-Founder of Coriolis, commented: “This investment presents a pivotal growth opportunity for Coriolis to realize our strategy and vision. The ability to leverage Frontier’s collective skills and expertise will be invaluable as we revolutionize the development process of biopharmaceutical drugs. Together with a strong suite of industry advisors and KKR’s global network and market knowledge, we will be able to position Coriolis for the future and move one step closer to our goal of making future therapies available to humankind efficiently and on time.”

KKR is investing in Coriolis Pharma through its KKR Health Care Strategic Growth Fund II, a $4.0 billion fund focused on investing in high-growth health care companies. KKR has a long track record of supporting health care companies globally, having invested approximately $19 billion in the sector since 2004.

The investment in Coriolis Pharma underscores KKR’s strong presence in the German-speaking DACH region, where KKR has invested more than €15 billion of long-term equity capital in over 30 companies since 1999. Currently, approximately 40 of KKR’s global portfolio companies operate in the DACH region.

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

About Flerie

Flerie is an active long-term global biotech and pharma investor based in Stockholm and London managing a portfolio of 30 companies in Europe, Israel and the US. Flerie’s evergreen investment strategy, operational expertise and network enables pioneering technologies in the drug development and services space to advance on their path to treating patients and commercialization. Flerie was founded in 2011 by Thomas Eldered, who also co-founded and built Recipharm to be one of the world’s top five pharmaceutical contract manufacturers. For more information, please visit www.flerie.com.

About Coriolis Pharma

Coriolis Pharma is a globally operating contract research and development organization (CRDO) and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs, including cell and gene therapy products and vaccines. It is the vision of Coriolis to revolutionize the development process of biopharmaceutical drugs by integrating innovative digital formulation approaches from drug development to commercial products. With its interdisciplinary team of highly skilled scientists and an expert scientific advisory board, Coriolis provides cutting-edge services and tailor-made solutions for its clients. Coriolis was founded in 2008 and currently employs more than 200 employees from over 36 nations around the world. For more information visit www.coriolis-pharma.com.

KKR media contact

Thea Bichmann
Mobile: +49 (0) 172 13 99 761
Email: kkr_germany@fgsglobal.com

Fabian Prietzel
Mobile: +49 (0) 171 86 01 411
Email: kkr_germany@fgsglobal.com

Coriolis media contact

Bettina von Klitzing-Stückle
Mobile: +49 (0) 151 52 61 38 97
Email: bettina.klitzing@coriolis-pharma.com

Source: KKR

Categories: News

Tags:

Azurity Pharmaceuticals acquires KKR-backed Slayback Pharma

KKR

WOBURN, MA – Azurity Pharmaceuticals, Inc. (“Azurity”) is pleased to announce the closing of its acquisition of Slayback Pharma LLC (“Slayback”) today from existing investors including KKR, a leading global investment firm, and Everstone Capital. Slayback is now a wholly-owned subsidiary of Azurity.

The acquisition brings together companies with complementary strengths, enhancing Azurity’s ability to realize its purpose of Serving Overlooked Patients. The combined development portfolios are expected to yield a significant number of new medicine launches over the coming years.

Azurity leverages its integrated capabilities and vast partner network to continually expand its broad commercial product portfolio and robust pipeline. The company’s patient-centric approach is evident in its diverse array of products catering to various medical needs, including cardiovascular, central nervous system, endocrinological, gastrointestinal, anti-infectives and oncology. Many of Azurity’s medicines are dose-form innovations for patients with needs that are not met by other commercially available therapies.

“I am delighted to announce this combination and the increased potential it brings to do more for overlooked patients,” said Richard Blackburn, CEO of Azurity. “The complementary expertise of the two companies in developing innovative dose forms will result in a strong pipeline of new medicines to meet the needs of patients. We will bring the commercial expertise of Azurity to Slayback’s pipeline and look forward to introducing an even wider range of dose-forms and formulations to meet a broader set of patient needs.”

“The combination of Slayback and Azurity is a union of highly complementary capabilities: Azurity’s innovative commercial acumen and Slayback’s exceptional R&D platform. I am proud of Slayback’s team, our track record of developing complex products with unmatched speed at scale, and the rich history we have built together. I am delighted to join forces with Azurity to help forge a combined entity that is truly one of a kind” added Ajay Singh, Founder and CEO of Slayback.

“We are pleased to add Slayback’s complementary product pipeline and robust R&D capabilities to Azurity. The acquisition of Slayback accelerates Azurity’s strategic growth plan and enhances our ability to launch multiple innovative new drug products into the market every year to serve overlooked patients,” said Jeff Edwards, Partner at QHP Capital, the majority owner of Azurity.

“We have enjoyed working closely with Ajay and Slayback’s impressive management team to scale and support the platform as a leading provider of complex pharmaceuticals,” said Ali Satvat, Partner and Global Head of Health Care Strategic Growth at KKR. “Together we have established an extensive pipeline that Azurity will further build upon, helping to increase accessibility to health care for patients.”

Greenhill & Co. served as financial advisor and White & Case served as legal advisor to Azurity.  Leerink Partners served as lead financial advisor and Raymond James as co-advisor to Slayback while Kirkland & Ellis served as legal advisor to Slayback.

About Azurity Pharmaceuticals:

Azurity is a privately-held pharmaceutical company specializing in providing innovative, high-quality medicines that serve overlooked patients. Azurity supplies a large number of products to treat a wide range of medical conditions. These include cardiovascular, central nervous system, endocrine, gastro-intestinal, anti-infective and oncology medicines. Many of Azurity’s medicines are dose-form innovations for patients with needs that are not met by other available products. Azurity’s medicines have benefited millions of people. For more information, please visit www.azurity.com.

About QHP Capital:

QHP Capital is an investor in technology and services companies in the life sciences and healthcare sectors. QHP traces its heritage back to Quintiles (now IQVIA) and NovaQuest Capital Management. QHP has built an investment platform to provide strategic capital and industry expertise in partnership with strong management teams. The investment team consists of seasoned investment and operational professionals with significant investment experience and deep life science and healthcare expertise. QHP benefits from an extensive network of industry experts and relationships that assist in identifying, analyzing, and growing QHP’s portfolio companies. QHP also manages the NovaQuest Private Equity funds. For more information, please visit www.qhpcapital.com.

Contacts:

For Azurity Pharmaceuticals
Ronald L. Scarboro
rscarboro@azurity.com


<< Back to Press Releases

Categories: News

Tags:

GBA Group expands range of toxicology services

Fields Group

Hamburg/Roßdorf, 20. September 2023. GBA Group is expanding its range of toxicology services for customers in the chemical, medical device and pharmaceutical industries with the acquisition of ICCR-Roßdorf GmbH (ICCR-Roßdorf) from investor FIELDS Group. This acquisition underlines GBA Group’s ambition to position itself broadly as an international life science service provider through targeted portfolio expansions and investment in leading CROs.

Today’s ICCR-Roßdorf GmbH (Institute for Competence Contract Research – Roßdorf) was founded in 1986 and has its headquarters with almost 100 employees in Roßdorf near Darmstadt. The focus of ICCR-Rossdorf is the investigation of the genotoxic potential of pharmaceuticals, agrochemicals, cosmetics and chemicals. For customers in the field of medical devices, the service portfolio is supplemented with modified protocols for the investigation of the effects of extracts.

Dr. Sabine Gorynia, Executive Vice President Pharma & Medical Devices, GBA Group, underlines the synergies resulting from the merger: “With more than 30 years of experience, one of the world’s leading Gentox providers enriches the portfolio and business network of GBA Group. We are pleased to further strengthen our growth in the preclinical area together with our colleagues from ICCR-Roßdorf and to be able to offer our national and international customers another important component in an even broader service portfolio.”

Dr. Markus Schulz, Managing Director of ICCR: “The constructive and open discussion in the run-up to the transaction showed that the closer cooperation between GBA Group and ICCR-Roßdorf offers great opportunities. This applies both to the broad use of the solutions and expertise we have developed in the toxicology field within the GBA Group and to joint projects in the development of innovative assays in new areas of application.”

 

About GBA Group

GBA Group is an international life science service company with more than 2,000 employees in 8 countries and a broad range of analytical, logistical and specialist services in the fields of pharmaceuticals, medical products, cosmetics, chemicals, food, drinking water and the environmental sustainability. The range of services offered by the GBA Group includes laboratory analytics, data management, special logistical services for clinical trials, as well as consulting services for private companies and public institutions in connection with their activities in the fields of research, product development, market development, and consumer protection. Through its work, the GBA Group makes a sustainable contribution to public health, the environment and society as a whole.

About FIELDS Group

FIELDS Group is an entrepreneurial, hands-on investor focused on developing businesses with potential. FIELDS invests in companies headquartered in the Benelux and DACH regions and achieves fundamental transformations with its team.

Categories: News

Tags:

Controlant announces $40 million in new financing from Apax Credit Funds

No Comments
Apax

Controlant, a global leader in real-time pharma supply chain monitoring and visibility technologies, today announced it has received $40m in financing to support future growth from Funds advised by Apax Credit, the credit-investing arm of Apax Partners LLP (“Apax”).

Controlant is a global leader in the digital transformation of pharma supply chains. The company’s vision is to deliver zero-waste supply chains for its partners and the planet through digitalisation, automation, and transformation of the pharma supply chain. Controlant‘s holistic solution framework encompasses cloud-enabled software platform, coupled with advanced IoT devices,  and cost-reducing operational services that increase supply chain efficiency and responsiveness while supporting quality, compliance, and sustainability efforts.

“As pharma companies continue to innovate at pace and introduce breakthrough medicines and vaccines, it is incredibly important that modern supply chains match this pace and serve as enablers in ensuring medicines reach patients safely, and sustainably. That is our vision, and we are working tirelessly to create the next generation of zero-waste supply chains for our pharma customers”, said Gisli Herjolfsson, CEO and co-founder, Controlant.  “We are thankful for Apax Credit’s support on this journey, which will enable us to accelerate our roadmap of innovative solutions for our customers rapidly evolving and complex supply chain needs.”

The financing will help the company to accelerate growth, expand its already comprehensive and market-leading offering to global customers, and capitalise on strong tailwinds in the supply chain technology sector.

“Apax’s credit strategy provides flexible capital solutions for stand-out businesses across Apax’s four core sectors. Leveraging insights from across Apax and Apax Credit, we were pleased to provide a tailored solution for Controlant, designed to help the company in its next phase of growth”, said Albert Costa Centena, Principal, Apax Credit. “We are excited to partner with the team, leveraging our sector insights, operational expertise, and the wider Apax platform to support a business at the cutting edge of real-time visibility technology for pharma supply chains.”

– Ends –

About Controlant

Controlant is a global leader in the digital transformation of pharma supply chains. Our vision is to deliver zero-waste supply chains for our partners and the planet through digitalization, automation, and transformation of the pharma supply chain.

Our validated real-time visibility platform, command center, services, and advanced IoT devices, are trusted by many of the world’s leading pharmaceutical and logistics companies to make their operations significantly more reliable, cost-effective, and sustainable. Ultimately, our solutions help get life-saving medicines to more patients, curing more diseases.

With over 500 employees of more than 40 nationalities, Controlant continues to expand globally. Founded in 2007 and backed by a strong investor base, Controlant generated around USD 133 million in revenues in 2022. More information at controlant.com

 

About Apax Credit and Apax

Established 10 years ago, Apax Credit is fully integrated into the wider Apax Platform, fully leveraging Apax’ 50 years of experience. Like the Apax Private Equity Funds, the Apax Credit Fund focuses on investments in four core sectors: Tech, Services, Healthcare and Internet/Consumer, and within each they identify attractive sub-sectors where they can offer differentiated propositions to companies, their management teams, and wider stakeholders. The Apax Credit strategy benefits from a flexible mandate, allowing the team to focus on the credit solutions that offer the best fit in each case. For further information, please visit: https://www.apax.com/create/strategies/apax-credit/

Apax Partners LLP (“Apax”) is a leading global private equity advisory firm. For 50 years, Apax has worked to inspire growth and ideas that transform businesses. The firm has raised and advised funds with aggregate commitments of more than $65 billion. The Apax Funds invest in companies across four global sectors of Tech, Services, Healthcare, and Internet/Consumer. These funds provide long-term equity financing to build and strengthen world-class companies. For further information about Apax, please visit www.apax.com.

GLOBAL MEDIA CONTACT

Katarina Sallerfors

t: +44 20 7872 6300

Luke Charalambous

t: +44 20 7872 6300

Categories: News

Tags:

Jeito Capital co-leads eur 65 million (USD 71 MILLION) financing in Corteria Pharmaceuticals, a French Biopharmaceutical company

Jeito Capital
  • Jeito Capital co-leads oversubscribed financing
  • Corteria, a late preclinical stage company, is developing first-in-class therapies with promising novel approaches for unaddressed heart failure subpopulations, addressing high unmet medical needs
  • Jeito Capital marks its first investment in the cardiovascular space, further diversifying its strong portfolio

Paris, France, September 7th 2023 – Jeito Capital (“Jeito”), a global leading investment firm dedicated to healthcare and biopharma, announced today that it is co-leading a EUR 65m (USD 71m[1]) Series A financing round in Corteria Pharmaceuticals (“Corteria” or the “Company”), a biopharmaceutical company specialized in the development of transformative therapies for unaddressed heart failure subpopulations.

The oversubscribed financing was co-led by new investors Jeito and Orbimed, with participation from existing investors Kurma Partners, Fountain Healthcare Partners, V-Bio Ventures, Invivo Capital, and Omnes Capital.

Corteria was founded in 2021 by Sanofi’s former head of cardiovascular research, Philip Janiak and Marie-Laure Ozoux, former cardiovascular project leader at Sanofi, around two cardiovascular programs in-licensed from Sanofi[2].

Proceeds from the financing will be used to advance the Company’s heart failure pipeline into the clinic.

Since its inception, Corteria’s pipeline has expanded rapidly and comprises today three first-in-class therapies:

  • A once-daily subcutaneous CRF2[3] agonist for the treatment of Worsening Heart Failure. It is anticipated that Corteria will bring this lead asset, into clinical trials to validate the treatment pathway in early 2024.
  • A once-monthly subcutaneous CRF2[3] agonist, specifically developed for Right Heart Failure treatment. This compound also holds potential for broader applications in chronic cardiometabolic diseases, particularly those with coexisting conditions such as obesity and sarcopenia.
  • An AVP (arginine vasopressin) neutralizing monoclonal antibody for the treatment of Acute Heart Failure with Hyponatremia.

Jeito Capital has partnered with Corteria Pharmaceuticals, reflecting its vision to champion promising French and European biopharma companies with the potential to become global market leaders especially in Europe and the US. This collaboration marks Jeito’s first investment in the cardiovascular space, where emerging innovations and a supportive regulatory environment offer transformative potential for patient outcomes. Andreas Wallnoefer, Partner at Jeito Capital and with strong industry experience in the cardiovascular field, will join Corteria’s Board of Directors.

Dr. Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital, commented: “With our first investment in the cardiovascular field, we are partnering with Corteria Pharmaceuticals, a French company with a global vision to address well-defined sub-populations of heart failure, with an urgent need for new and effective treatments. Corteria’s strong pipeline of assets, backed by a dedicated and highly experienced team with a proven track record in cardiovascular development, represents an exciting opportunity to expand treatment options. Their commitment to transformative therapies as a leading French biopharma with global aspirations perfectly aligns with Jeito’s mission, and we see great potential to make a meaningful difference in patient lives.”

Andreas Wallnoefer, Partner at Jeito Capital added: “Despite current treatments, heart failure is a progressing disease that impacts severely the lives of many patients and remains one of the leading causes of mortality worldwide. Corteria focuses on translating important therapeutic innovations in cardiology into clinical practice. Our investment in Corteria reflects Jeito’s commitment to address significant unmet needs in the realm of cardiology. We are excited to join forces with Corteria’s dedicated team to develop a portfolio of medicines with important clinical benefits for patients.”

“This financing marks a major milestone in our mission to bring therapies to heart failure subpopulations with high unmet needs,” said Philip Janiak, Founder and CEO of Corteria Pharmaceuticals. “We are extremely grateful to Jeito and OrbiMed as our new investors for their trust in our science and team and to our existing investors for their support and commitment since inception. We are looking forward to working all together to develop next generation transformative therapeutics.”

About Jeito Capital

Jeito Capital is a global leading Private Equity company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access globally, especially in Europe and the United States. Jeito Capital has €534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United States.

For more information, please visit www.jeito.life or follow us on Twitter or LinkedIn.

About Corteria Pharmaceuticals

Founded in 2021, Corteria Pharmaceuticals is a privately held biopharmaceutical company developing first-in-class drugs in heart failure subpopulations. Despite some improvements in the management of this serious disease, the prevalence of heart failure keeps increasing with more than 60 million patients worldwide. Corteria’s strategy implies innovative patient stratification and target selection based on human evidence and a better understanding of the disease biology in patients with a focus on worsening and acute heart failure and right heart failure.

More information available at: www.corteriapharma.com

[1] Applying an 1.0886 EUR/USD exchange rate as of 30 August 2023 (Banque de France) rounded to $71m

[2] CRF2 peptide agonist and AVP neutralizing monoclonal antibody programs

[3] Corticotropin-releasing hormone receptor 2

For further information please contact:

Jeito Capital
Rafaèle Tordjman
Assia Mouhout, EA
assia@jeito.life
Tel: +33 6 76 49 37 94

Consilium Strategic Communications
Mary-Jane Elliott /
Davide Salvi / Kris Lam
Jeito@consilium-comms.com
Tél. : +44 (0) 20 3709 5700 

Categories: News

Tags:

Recommended cash acquisition of Dechra Pharmaceuticals plc approved by the requisite majority of Dechra shareholders

eqt

The requisite majority of Dechra shareholders approved the recommended cash acquisition of Dechra Pharmaceuticals plc (the “Acquisition”) at the court meeting and general meeting, each held on 20 July

Each Dechra shareholder will be entitled to receive 3,875 pence in cash for each Dechra share held under, and subject to, the terms of the Acquisition set out in the scheme document, valuing the ordinary share capital of Dechra at approximately GBP 4.459 billion on a fully diluted basis

EQT Private Equity believes it is well positioned to support Dechra’s next phase of growth, bringing to bear its experience from investments into the animal health value chain

Dechra Pharmaceuticals plc (“Dechra” or the “Company”) announced on 20 July 2023 that the requisite majority of its shareholders have approved the recommended cash acquisition by Freya Bidco Limited for the Company (the “Acquisition”). Freya Bidco Limited is a newly formed company to be indirectly owned by (i) EQT X EUR SCSp and EQT X USD SCSp, each acting through its manager (gérant) EQT Fund Management S.à r.l., and (ii) Luxinva S.A., a wholly owned subsidiary of the Abu Dhabi Investment Authority (“ADIA”).

At a court meeting and general meeting held on 20 July, the requisite majority of Dechra shareholders approved the scheme of arrangement in respect of the Acquisition and a special resolution to implement it. Subject to the terms and conditions set out in the scheme document published on 26 June 2023, under the terms of the Acquisition each Dechra shareholder will be entitled to receive 3,875 pence in cash for each Dechra share held, valuing the ordinary share capital of Dechra at approximately GBP 4.459 billion on a fully diluted basis.

Background to the recommended cash acquisition
Dechra is a global developer, manufacturer and supplier of products relating to the companion animal, equine, food producing animal and nutrition categories. Founded 25 years ago and listed on the London Stock Exchange in 2000, today Dechra has operations in 26 countries and nearly 2,500 employees.

EQT Private Equity believes it is well positioned to support Dechra’s next phase of growth by virtue of its insights and experience investing in the animal health value chain. EQT Private Equity plans to provide, where needed, additional investment in Dechra’s innovative pipeline and further supporting global expansion.

Anthony Santospirito, partner in the EQT Private Equity advisory team, said: “Dechra is a high-quality, innovative business founded in the UK with an impressive global footprint. With medical innovation accelerating and pet ownership increasing, the animal health sector is expected to benefit from long-term growh and we believe Dechra is well positioned to participate in this significant opportunity. We plan to support Dechra’s talented management team in accelerating their business strategy.”

Certain of the conditions to the Acquisition remain and can be found in the Scheme Document here. As noted in the Dechra announcement, the regulatory conditions in relation to Spain and Germany have now been satisfied.

With this acquisition, EQT X (target fund size of EUR 20.0 billion and a hard cap of EUR 21.5 billion) is expected to be 20-25 percent invested (including closed and/or signed investments, announced public offers, if applicable, and less any syndication regarding this acquisition as at the date of this press release) based on its target fund size, subject to customary regulatory approvals.

Click here for more information.

Contacts
Finn McLaughlan, finn.mclaughlan@eqtpartners.com, +44 771 534 1608

EQT Press Office, press@eqtpartners.com, +46 8 506 55 334

Important notice
The information in respect of the EQT X fund (“EQT X”) contained herein does not constitute an offer to sell, nor a solicitation of an offer to buy, any security, and may not be used or relied upon in connection with any offer or solicitation of EQT X. Any offer or solicitation in respect of EQT X will be made only through a confidential private placement memorandum and related documents which will be furnished to qualified investors on a confidential basis in accordance with applicable laws and regulations. The information in respect of EQT X contained herein is not for publication or distribution to persons in the United States of America. Any securities of EQT X referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold without registration thereunder or pursuant to an available exemption therefrom. Any offering of securities of EQT X to be made in the United States would have to be made by means of an offering document that would be obtainable from the issuer or its agents and would contain detailed information about the issuer of the securities and its management, as well as financial information. Any EQT X securities may not be offered or sold in the United States absent registration or an exemption from registration.

For the avoidance of doubt, neither the content of this website nor any website accessible from hyperlinks is incorporated by reference or forms part of this press release.

Categories: News

Tags:

Bain Capital Private Equity to acquire FIS

BainCapital

LONDON and MONTECCHIO MAGGIORE, Italy – 7th July 2023 – Bain Capital Private Equity (“Bain Capital”), a leading global private investment firm, and Nine Trees Group S.p.A. (“NTG”)¸ the holding company of the Ferrari Family, announce that they have reached binding agreements (subject to customary conditions precedent) for the acquisition by Bain Capital of the entire NTG’s shareholding in FIS – Fabbrica Italiana Sintetici S.p.A. (“FIS” or the “Company”), a leading developer and manufacturer of small molecule active pharmaceutical ingredients (APIs) and intermediates.

 

Founded in 1957 by the Ferrari Family in Montecchio Maggiore, FIS has a long history of pharmaceutical technical innovation and is recognised globally for its differentiated capabilities and deep technical expertise. Over the years FIS has become the development and manufacturing partner of choice for top blue-chip pharmaceutical companies around the world for custom and generic API synthesis. In 2022, the Company generated sales of approximately €700M in 70 countries and more than 300 customers around the globe, with a network of three world-class manufacturing facilities based in Italy, employing more than 2,000 people, including 250 R&D scientists, and having in its portfolio 25 of the 200 best-selling small molecules in the world.

 

In over 60 years of history, the Ferrari Family has created, developed and continuously supported FIS – Fabbrica Italiana Sintetici, leading it to become the leader of the small molecule and active pharmaceutical ingredients sector in Italy, and one of the best-in-class developers and manufacturers in Europe and Globally. Today FIS is ideally positioned to further grow and expand internationally to become one of the world leaders in the APIs / small molecule industry. The Ferrari Family has found in Bain Capital an ideal partner who can drive the future growth of the business into the next phase, considering its significant industrial experience and operational resources. We are thankful to the FIS Management team led by Michele Gavino (CEO) and Manuel Barreca (CFO) and to all FIS employees and stakeholders for the successful path carried on together so far. We would also like to thank all the people that have contributed to this successful transaction” said Giampaolo Ferrari, Alessandro Ferrari and Andrea Cappellato Ferrari, respectively Chairman and Managing Directors of NTG and FIS.

 

FIS Management Team is very proud of the results achieved by the Company in recent years and the work that we are doing together with our customers and partners in developing cutting-edge technologies and continuing to create sustainable and responsible innovation in the APIs and small-molecule sector. We thank the Ferrari Family for all the continued support provided to the Company and we are looking forward to be working with Bain Capital and drive FIS to further grow and become the global industry leader in the APIs / small molecule industry”, said Michele Gavino, CEO of FIS and Manuel Barreca, CFO of FIS.

 

Our investment in FIS marks a strategically important transaction for Bain Capital Private Equity in Europe, consistent with our thematic investment approach to the pharmaceutical industry. We were impressed by FIS’ deep expertise in complex chemistry, differentiated development capabilities, and strong relationships with Pharma and Biotech customers. We have high conviction in the industry’s growth prospects and are excited to support the development and manufacture of innovative and life-saving therapies for patients worldwide,” said Christina Dix and Benjamin Kunstler, Partners and Co-Heads of European Healthcare at Bain Capital Private Equity.

 

The acquisition of FIS is perfectly aligned with our long track record of successful partnerships with family-owned business and further builds on our successful Italian franchise. We are honoured to partner with the Ferrari family and to accompany FIS in its next phase of growth,” said Ivano Sessa, Partner at Bain Capital Private Equity.

NTG’s financial advisors were Houlihan Lokey and Zulli Tabanelli & Associati. Orsingher Ortu Avvocati Associati provided legal advice and PwC worked on the vendor due diligence.

 

Bain Capital has been advised by Mediobanca, Nomura, Latham & Watkins, Advancy, Bain & Company, PwC, Pirola Pennuto Zei & Associati and InterPharmaLink.

 

The transaction remains subject to approvals by competent regulatory authorities.

 

 

About FIS – Fabbrica Italiana Sintetici / NTG:

FIS – Fabbrica Italiana Sintetici S.p.A.

FIS (FIS – Fabbrica Italiana Sintetici SpA) was founded in 1957 in Montecchio Maggiore (VI) by the Ferrari family, which maintains ownership to this day. It’s a leader in Italy and one of the major operators in Europe in the production of active ingredients for the industry pharmaceutical and operates 3 plants in Italy: Montecchio Maggiore (VI), Termoli (CB) and Lonigo (VI). FIS belongs to the Nine Trees Group, and is also present in the USA (FIS North America), Japan (FIS Japan), and in China with a representative office. With a turnover of around 700 million euros, the company now has over 2000 employees, of which 250 are dedicated to research and development. Michele Gavino has led the company as Chief Executive Officer since February 2021.

 

For more information, visit: https://www.fisvi.com

 

 

About Bain Capital Private Equity:

Bain Capital Private Equity has partnered closely with management teams to provide the strategic resources that build great companies and help them thrive since its founding in 1984. Bain Capital Private Equity’s global team of more than 280 investment professionals creates value for its portfolio companies through its global platform and depth of expertise in key vertical industries including healthcare, consumer/retail, financial and business services, industrials, and technology, media and telecommunications. Bain Capital has 23 offices on four continents. Since its inception, the firm has made primary or add-on investments in more than 1,150 companies. In addition to private equity, Bain Capital invests across multiple asset classes, including credit, public equity, venture capital and real estate, managing approximately $165 billion in total assets and leveraging the firm’s shared platform to capture opportunities in strategic areas of focus.

 

For more information, please visit: www.baincapitalprivateequity.com

Categories: News

Tags:

EQT Private Equity to sell Ellab, following transformation into a leading validation & monitoring provider for the Biotech and Pharmaceutical industries

eqt
  • EQT Private Equity, together with its co-shareholders, to sell Ellab to Novo Holdings
  • Since EQT Private Equity invested in 2019, Ellab has transformed into a full-suite provider of validation and monitoring solutions and services, serving all the top 20 biotech companies and all the top 40 pharmaceutical companies globally
  • Transformation has resulted in Ellab tripling its revenues, EBITDA and number of employees, while experiencing approximately 20% annual organic revenue growth and completing 15 add-on acquisitions

EQT is pleased to announce that EQT Mid Market Europe (“EQT Private Equity”), together with its co-shareholders, have agreed to sell Ellab (“Ellab” or the “Company”) to Novo Holdings, which is responsible for managing the assets and wealth of the Novo Nordisk Foundation, one of the world’s largest philanthropic enterprise foundations.

Headquartered in Hillerød, Denmark, Ellab provides validation and monitoring solutions and services for biotech and pharmaceutical processes. Its solutions and services measure and document parameters such as temperature, pressure, and carbon dioxide. These help clients to ensure consumer safety and regulatory compliance while reducing time to market and the risk of product loss.

EQT Private Equity acquired Ellab in September 2019 with a vision to accelerate the Company’s growth journey by solidifying its core offering within validation solutions, while expanding into monitoring solutions and field services & consulting. Today, Ellab has transformed into a full solution provider, while tripling its revenues, EBITDA and employee base. It counts all the top 20 biotech companies and all the top 40 pharmaceutical companies globally as clients.

During EQT Private Equity’s ownership, Ellab shifted its customer focus towards high-growth industries such as biotech, cell & gene therapies, and contract development & manufacturing organizations. At the same time, it invested significantly in research & development, digitalization and personnel to strengthen the organization, while acquiring 15 companies around the globe. The Company has also defined a clear sustainability strategy, for instance by committing to the Science Based Targets initiative that requires Ellab to set greenhouse gas emission reduction targets in line with the 1.5° pathway described in the Paris Agreement.

Rikke Kjær Nielsen, Partner within EQT Private Equity’s Advisory Team, said, “Ellab’s solutions play a vital role in ensuring accuracy and compliance in its clients’ biotech and pharmaceutical processes, which is key for these companies. This was true when we first invested in Ellab and remains the case today. The difference now is the scale and flexibility that Ellab offers, as it has transformed into a full-suite provider of validation and monitoring solutions and services. It has been a privilege to partner with the entire Ellab management team, who have built a company with a strong culture and customer focus, dedication to innovation and commitment to consumer safety. We believe Novo Holdings is a great partner for the next stage of Ellab’s growth journey and we wish them all the best in the future.”

Ludvig Enlund, CEO of Ellab, said “With EQT Private Equity’s support, Ellab has transformed into a truly leading global player with best-in-class software and hardware for validation and monitoring for the life sciences industry, and today also holds a strong position within field services & consulting. We are grateful for the partnership and now look forward to continuing our journey with Novo Holdings.”

The transaction is subject to regulatory approval. Closing of the transaction is expected in Q3 2023.

Contact

EQT Press Office, press@eqtpartners.com, +46 8 506 55 334

About EQT
EQT is a purpose-driven global investment organization with EUR 119 billion in assets under management within two business segments – Private Capital and Real Assets. EQT owns portfolio companies and assets in Europe, Asia-Pacific and the Americas and supports them in achieving sustainable growth, operational excellence and market leadership.

More info: www.eqtgroup.com
Follow EQT on LinkedIn, Twitter, YouTube and Instagram

About Ellab
Headquartered in Hillerød, Denmark, Ellab provides Validation and Monitoring Solutions and Services used for measuring and documenting critical parameters such temperature, pressure and CO2 in mainly biotech and pharma processes. The Company serves all of the top 20 biotech companies and all of the top 40 pharma companies globally helping them ensure consumer safety and regulatory compliance, while reducing time to market and the risk of product loss.

More info: https://www.ellab.com/

About Novo Holdings A/S
Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.

Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novozymes A/S and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seeds, Venture, Growth, and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development.

As of year-end 2022, Novo Holdings had total assets of EUR 108 billion.
www.novoholdings.dk 

About the Novo Nordisk Foundation
Established in Denmark in 1924, the Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives. The vision of the Foundation is to improve people’s health and the sustainability of society and the planet. The Foundation’s mission is to progress research and innovation in the prevention and treatment of cardiometabolic and infectious diseases as well as to advance knowledge and solutions to support a green transformation of society.

www.novonordiskfonden.dk/en

Categories: News

Tags:

Eurazeo provides a unitranche financing for Keensight Capital’s acquisition of Inke

Eurazeo

Eurazeo, through its Private Debt team, joined forces with Keensight Capital to support the acquisition of Inke through a unitranche credit facilty. The transaction is the 8th sponsor-led financing arranged in the Iberian Peninsula.

Set up in 1980 and based in Castellbisbal near Barcelona (Spain), Inke is the leader in micronization of complex Active Pharmaceutical Ingredients (“APIs”). The group has a specialization in inhalation APIs with a differentiated first-to-market approach. Inke combines a high regulatory expertise with close-knit relationships with major pharmaceutical companies worldwide, including in core markets such as the US, the EU and the highly regulated Japanese market.

Arnaud Maisonneuve, Managing Director, Eurazeo said:

« Inke has established itself as a leading manufacturer of complex micronized bronchodilators, demonstrating a high consistency of compliance, quality and differentiated capabilities to serve a blue-chip and global customer base. We feel confident that Inke will prosper and continue to expand its portfolio of APIs and its end-markets with the support of Keensight Capital. »

ABOUT EURAZEO
• Eurazeo is a leading global investment company, with a diversified portfolio of €35 billion in assets under management, including nearly €24.7 billion from third parties, invested in around 600 companies. With its considerable private equity, private debt as well as real estate and infrastructure asset expertise, Eurazeo accompanies companies of all sizes, supporting their development through the commitment of its nearly 410 professionals and by offering deep sector expertise, a gateway to global markets, and a responsible and stable foothold for transformational growth. Its solid institutional and family shareholder base, robust financial structure free of structural debt, and flexible investment horizon enable Eurazeo to support its companies over the long term.
• Eurazeo has offices in Paris, New York, London, Frankfurt, Berlin, Milan, Madrid, Luxembourg, Shanghai, Seoul, Singapore and Sao Paulo.
• Eurazeo is listed on Euronext Paris.
• ISIN: FR0000121121 – Bloomberg: RF FP – Reuters: EURA.PA

Categories: News

Tags: